Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 May;115(2):349–355. doi: 10.1111/j.1476-5381.1995.tb15884.x

Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.

S W Martin 1, K J Broadley 1
PMCID: PMC1908310  PMID: 7670737

Abstract

1. The renal vascular responses of the rat isolated perfused kidney to the dopamine D1-receptor agonists, dopexamine and fenoldopam, were examined. 2. Both kidneys were perfused in situ at constant flow rate (11 ml min-1) with Krebs-bicarbonate solution at 37 degrees C. The perfusion pressure was monitored and to enable vasodilator responses to be measured, the resting perfusion pressure was raised by infusing noradrenaline (6 x 10(-9) M). 3. Dose-related vasodilator responses to bolus doses of dopexamine and fenoldopam were obtained. However, these were not antagonized by the D1-receptor antagonist, SCH 23390, indicating that D1-receptors were not involved. 4. Bolus doses of the alpha 1-adrenoceptor antagonist, prazosin, caused similar dose-related vasodilator responses indicating the possibility that alpha 1-adrenoceptor blocking properties of dopexamine and fenoldopam were responsible for the vasodilatation. 5. alpha-Adrenoceptor blockade by dopexamine and fenoldopam was confirmed by the parallel displacement of dose-response curves for the vasopressor responses to noradrenaline. pA2 values were determined by Schild analysis for dopexamine, fenoldopam and prazosin antagonism of noradrenaline in the presence of neuronal (cocaine, 10(-5) M) and extraneuronal uptake blockade (metanephrine, 10(-5) M). The values were 6.23, 6.02 and 8.91, respectively. Schild plot slopes of unity were obtained for dopexamine and fenoldopam indicating competitive antagonism. A slope of greater than unity for prazosin may be explained by the lack of equilibrium conditions associated with bolus doses of noradrenaline, the responses of which are affected more by the high affinity antagonist, prazosin, than the two lower affinity antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blinks J. R. Evaluation of the cardiac effects of several beta adrenergic blocking agents. Ann N Y Acad Sci. 1967 Feb 10;139(3):673–685. doi: 10.1111/j.1749-6632.1967.tb41237.x. [DOI] [PubMed] [Google Scholar]
  3. Blue D. R., Jr, Clarke D. E. Slow off-rate of prazosin accounts for deviations from competitive antagonism in the isolated perfused kidney of rat. Gen Pharmacol. 1992 Sep;23(5):815–821. doi: 10.1016/0306-3623(92)90230-h. [DOI] [PubMed] [Google Scholar]
  4. Brown R. A., Dixon J., Farmer J. B., Hall J. C., Humphries R. G., Ince F., O'Connor S. E., Simpson W. T., Smith G. W. Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors. Br J Pharmacol. 1985 Jul;85(3):599–608. doi: 10.1111/j.1476-5381.1985.tb10554.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cambridge D., Davey M. J., Massingham R. Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Br J Pharmacol. 1977 Mar;59(3):514P–515P. [PMC free article] [PubMed] [Google Scholar]
  6. Furchgott R. F. The pharmacological differentiation of adrenergic receptors. Ann N Y Acad Sci. 1967 Feb 10;139(3):553–570. doi: 10.1111/j.1749-6632.1967.tb41229.x. [DOI] [PubMed] [Google Scholar]
  7. Hahn R. A., Wardell J. R., Jr, Sarau H. M., Ridley P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther. 1982 Nov;223(2):305–313. [PubMed] [Google Scholar]
  8. Hilditch A., Drew G. M., Naylor R. J. SCH 23390 is a very potent and selective antagonist at vascular dopamine receptors. Eur J Pharmacol. 1984 Jan 27;97(3-4):333–334. doi: 10.1016/0014-2999(84)90471-0. [DOI] [PubMed] [Google Scholar]
  9. Imbs J. L., Schmidt M., Ehrhardt J. D., Schwartz J. The sympathetic nervous system and renal sodium handling: is dopamine involved? J Cardiovasc Pharmacol. 1984;6 (Suppl 1):S171–S175. doi: 10.1097/00005344-198400061-00027. [DOI] [PubMed] [Google Scholar]
  10. Langer S. Z., Trendelenburg U. The effect of a saturable uptake mechanism on the slopes of dose-response curves for sympathomimetic amines and on the shifts of dose-response curves produced by a competitive antagonist. J Pharmacol Exp Ther. 1969 May;167(1):117–142. [PubMed] [Google Scholar]
  11. Mitchell P. D., Smith G. W., Wells E., West P. A. Inhibition of Uptake1 by dopexamine hydrochloride in vitro. Br J Pharmacol. 1987 Oct;92(2):265–270. doi: 10.1111/j.1476-5381.1987.tb11320.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nakamura S., Kohli J. D., Rajfer S. I. Alpha-adrenoceptor blocking activity of fenoldopam (SK&F 82526), a selective DA1 agonist. J Pharm Pharmacol. 1986 Feb;38(2):113–117. doi: 10.1111/j.2042-7158.1986.tb04522.x. [DOI] [PubMed] [Google Scholar]
  13. Nedergaard O. A. Inhibition of 3H-noradrenaline accumulation by dopexamine hydrochloride in the isolated aorta of the rabbit. Naunyn Schmiedebergs Arch Pharmacol. 1989 Sep;340(3):270–273. doi: 10.1007/BF00168509. [DOI] [PubMed] [Google Scholar]
  14. Ohlstein E. H., Zabko-Potapovich B., Berkowitz B. A. The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist. Eur J Pharmacol. 1985 Dec 3;118(3):321–329. doi: 10.1016/0014-2999(85)90143-8. [DOI] [PubMed] [Google Scholar]
  15. Schmidt M., Krieger J. P., Giesen-Crouse E. M., Imbs J. L. Vascular effects of selective dopamine receptor agonists and antagonists in the rat kidney. Arch Int Pharmacodyn Ther. 1987 Apr;286(2):195–205. [PubMed] [Google Scholar]
  16. Smith G. W., O'Connor S. E. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride). Am J Cardiol. 1988 Aug 11;62(5):9C–17C. doi: 10.1016/s0002-9149(88)80061-4. [DOI] [PubMed] [Google Scholar]
  17. Ventura H. O., Messerli F. H., Frohlich E. D., Kobrin I., Oigman W., Dunn F. G., Carey R. M. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation. 1984 Jun;69(6):1142–1145. doi: 10.1161/01.cir.69.6.1142. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES